References:
1.Bruix J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014
2.Jeong, S. W. et al. "Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis." Gut Liver. 2013 Nov; 7(6): 696–703
3.Alsina A. et al. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2020 Jan;9(1):93-104. doi: 10.1159/000504624
4.Cheng A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. ASCO-GI 2021 and J Hepatol 2022; 76 (4): 862-873
5.Abou-Alfa G.K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8). doi: 10.1056/EVIDoa2100070
6.Breder, V. V. et. Al. , IMbrave150: Exploratory Efficacy and Safety Results of Hepatocellular Carcinoma (HCC) Patients With Main Trunk and/or Contralateral Portal Vein Invasion (Vp4) Treated With Atezolizumab + Bevacizumab vs Sorafenib in a Global Phase III Study ASCO Annual Meeting. June 4–8, 2021. Abstract #4073
מוגש מטעם רוש פרמצבטיקה (ישראל) בע"מ.
הירשמו לקבלת עדכונים בנושאים שעלו בכתבה
